Ameco Research analyst suggests that the global market for Anti-Biofilm Wound Dressing is anticipated to reach USD 2,190 Million by 2030 with a CAGR of more than 9% throughout the predicted years
According to Diabetes UK statistics from 2016, there were 59,000 active foot ulcer cases in England, with 135-foot amputations being diagnosed every week. With such a widespread issue, wound care must be both clinically and financially effective in order to help diabetic foot ulcers heal before they cause irreversible damage. The increasing prevalence of foot ulcers due to diabetes is the main cause behind the robust growth of the global anti-biofilm wound dressing industry. Diabetic foot issues contribute to both mortality and morbidity in the diabetic population, putting patients and the community at large under a significant physical, physiological, and financial strain. Foot difficulties account for 24.4 percent of overall health-care spending among diabetics, with the total cost of treating diabetic foot complications nearing US$ 11 billion in the United States and US$ 456 million in the United Kingdom. In addition, the global occurrence of chronic disorders is also expected to boost the demand for the market. For instance, according to the Center for Disease Control and Prevention, 6/10 adults in the United States have a chronic illness, and 4/10 adults have two or more chronic disorders. Furthermore, chronic diseases are the largest cause of disability and mortality, as well as a foremost contributor to the country's annual healthcare costs of US$ 3.5 trillion.
Request for a sample of this premium research report @ https://www.amecoresearch.com/sample/276615
The global anti-biofilm wound dressing market is expanding due to an increase in the frequency of chronic illnesses such as cancer and diabetes. Diabetes affected 537 million individuals (20-79 years) in 2021, accounting for one out of every ten people. By 2030, this number is expected to climb to 643 million, and by 2045, to 783 million. In addition, diabetes cost the US economy at least US$ 966 billion in health care costs in the last 15 years, a 316 percent rise. On the other hand, in 2021, the United States will have 1.9 million new cancer cases diagnosed and 608,570 cancer fatalities. Following cancer surgery, the majority of surgical wounds are large and deep, resulting in exudates that must be handled on a daily basis. Wound dressings with anti-biofilm properties, such as iodine and silver-based wound dressings, help in wound management and infection prevention. As a result, rising chronic sickness rates are expected to boost product demand, propelling the global anti-biofilm wound dressing market forward.
According to Frontiers Media S.A. research, implanted devices are extensively utilized in orthopedic and trauma surgery to restore function and aid in the healing of damaged bones. These procedures result in a more quick and precise restoration of function, which enhances the quality of life for those who are impacted. The increase of war-related wounds needs research and technological development to address biofilm techniques for managing multi-drug resistant bacteria contaminating chronic wounds, as aging and obesity place a considerable load on wound care. The worldwide anti-biofilm wound dressing market benefits from such aspects.
Global Anti-Biofilm Wound Dressing Market Scope
Mode of mechanism, application, and geography are the three components that make up the anti-biofilm wound dressing market. Based on the mode of mechanism, the market is divided into biological (lactoferrin, dispersin B, and bacteriophage), chemical (iodine, ionic silver, and Ethylenediaminetetraacetic acid (EDTA)), and physical (pulse electrical field, manual debridement, and ultrasound debridement). Among them, the chemical segment is likely to achieve a substantial market share in 2021. The high growth in the segment is ascribed due to an increase in the number of surgeries and the incidence of chronic wounds around the world.
Based on application, the market is split into acute wounds and chronic wounds. By application, acute wounds were the leading segment in 2021. Incisions, burns, abrasions, scratches, and puncture wounds are examples of acute lesions to the skin that occur suddenly. These wounds can occur anywhere on the body and range in size from little scratches to serious wounds.
North America, Latin America, Asia-Pacific, Europe, and the Middle East & Africa (MEA) are the regional categorization of the worldwide anti-biofilm wound dressing market. Based on Ameco’s analysis, the North American region accounted for the leading market share in 2021. Some of the reasons projected to drive the market include the rising prevalence of sports injuries, the rising number of traffic accidents, and the presence of numerous important competitors in the region. Furthermore, a well-developed healthcare infrastructure, as well as favorable reimbursement policies, is expected to propel market growth throughout the projection period.
Meanwhile, the Asia-Pacific region is expected to attain the fastest growth rate during the predicted years 2022 – 2030. The presence of growing countries such as Japan, India, and China in this area is expected to propel market expansion. The demand for wound closure is increasing as a result of a high influx of medical tourists requiring surgical procedures, as well as the requirement for early discharge.
The top players offered in the report include Coloplast A/S, 3M, ConvaTec Group plc, Smith & Nephew PLC, BioVersys AG, URGO, Mölnlycke Health Care AB, and Imbed Biosciences.
To receive personalized service, please share your research needs here@ https://www.amecoresearch.com/enquiry-before-buy/276615
Buy this premium research report - https://www.amecoresearch.com/buy/276615
USA: +1 347 474 3864
India: +91 8983225533